The presence of the JAK2 V617F mutation, a positive history for thrombosis or the employment of cytoreduction versus antiplatelet therapy did not impact on CECs levels in ET, nor were CECs levels associated with age, sex, ET duration or complete blood count parameters. This evidence concerns the gene JAK2 and essential thrombocythemia.